Submit to Special Issue Submit Abstract to Special Issue Review for Bioengineering Edit a Special Issue

Journal Menu

Journal Browser

Special Issue "Bioengineering Technologies to Advance Reproductive Health"

Print Special Issue Flyer
Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of Bioengineering (ISSN 2306-5354). This special issue belongs to the section "Regenerative Engineering".

Deadline for manuscript submissions: 30 September 2023 | Viewed by 3674

Share This Special Issue

Special Issue Editor

Dr. Monica M Laronda

E-Mail Website
Guest Editor

1. Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
2. Stanley Manne Children’s Research Institute, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL 60611, USA
Interests: reproductive biology; biofabrication; stem cells; fertility preservation; endocrinology; regenerative medicine; gonadal development

Special Issue Information

Dear Colleagues,

Over the last several years, engineering technologies and bioengineered systems have been used to investigate the physical properties of reproductive tissues, study the dynamics of gametogenesis, and integrate multitissue systems. The purpose of this Special Issue is to identify recent advancements in reproductive biology and regenerative medicine through bioengineering. Topics for publication include the use of engineered microenvironments or materials to interrogate the molecular mechanisms or physiology of reproductive organs or cells, the use of microfluidics to integrate multiple tissues and support gamete quality selection or fertilization, and the use of engineering technologies to characterize the physical properties of reproductive tissues.

Original research submissions are highly encouraged, and review articles that focus on research from the last five years as well as conceptualize the promise of future contributions to understanding reproductive biology and supporting future innovations in regenerative medicine will also be considered.

Dr. Monica M Laronda
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Bioengineering is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

engineered microenvironment
scaffolds
reproductive biology
fertilization
pregnancy
microfluidics
tissue engineering
biofabrication
regenerative medicine

Published Papers (3 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

Open AccessArticle

Encapsulated Allografts Preclude Host Sensitization and Promote Ovarian Endocrine Function in Ovariectomized Young Rhesus Monkeys and Sensitized Mice

James R. Day

Colleen L. Flanagan

Anu David

Dennis J. Hartigan-O’Connor

Mayara Garcia de Mattos Barbosa

and

Bioengineering 2023, 10(5), 550; https://doi.org/10.3390/bioengineering10050550 - 03 May 2023

Viewed by 492

Abstract

Transplantation of allogeneic donor ovarian tissue holds great potential for female cancer survivors who often experience premature ovarian insufficiency. To avoid complications associated with immune suppression and to protect transplanted ovarian allografts from immune-mediated injury, we have developed an immunoisolating hydrogel-based capsule that supports the function of ovarian allografts without triggering an immune response. Encapsulated ovarian allografts implanted in naïve ovariectomized BALB/c mice responded to the circulating gonadotropins and maintained function for 4 months, as evident by regular estrous cycles and the presence of antral follicles in the retrieved grafts. In contrast to non-encapsulated controls, repeated implantations of encapsulated mouse ovarian allografts did not sensitize naïve BALB/c mice, which was confirmed with undetectable levels of alloantibodies. Further, encapsulated allografts implanted in hosts previously sensitized by the implantation of non-encapsulated allografts restored estrous cycles similarly to our results in naïve recipients. Next, we tested the translational potential and efficiency of the immune-isolating capsule in a rhesus monkey model by implanting encapsulated ovarian auto- and allografts in young ovariectomized animals. The encapsulated ovarian grafts survived and restored basal levels of urinary estrone conjugate and pregnanediol 3-glucuronide during the 4- and 5-month observation periods. We demonstrate, for the first time, that encapsulated ovarian allografts functioned for months in young rhesus monkeys and sensitized mice, while the immunoisolating capsule prevented sensitization and protected the allograft from rejection. Full article

(This article belongs to the Special Issue Bioengineering Technologies to Advance Reproductive Health)

► Show Figures

Figure 1

Open AccessArticle

Proteomic Profiling of Fallopian Tube-Derived Extracellular Vesicles Using a Microfluidic Tissue-on-Chip System

and

Bioengineering 2023, 10(4), 423; https://doi.org/10.3390/bioengineering10040423 - 27 Mar 2023

Viewed by 1829

Abstract

The human fallopian tube epithelium (hFTE) is the site of fertilization, early embryo development, and the origin of most high-grade serous ovarian cancers (HGSOCs). Little is known about the content and functions of hFTE-derived small extracellular vesicles (sEVs) due to the limitations of biomaterials and proper culture methods. We have established a microfluidic platform to culture hFTE for EV collection with adequate yield for mass spectrometry-based proteomic profiling, and reported 295 common hFTE sEV proteins for the first time. These proteins are associated with exocytosis, neutrophil degranulation, and wound healing, and some are crucial for fertilization processes. In addition, by correlating sEV protein profiles with hFTE tissue transcripts characterized using GeoMx^® Cancer Transcriptome Atlas, spatial transcriptomics analysis revealed cell-type-specific transcripts of hFTE that encode sEVs proteins, among which, FLNA, TUBB, JUP, and FLNC were differentially expressed in secretory cells, the precursor cells for HGSOC. Our study provides insights into the establishment of the baseline proteomic profile of sEVs derived from hFTE tissue, and its correlation with hFTE lineage-specific transcripts, which can be used to evaluate whether the fallopian tube shifts its sEV cargo during ovarian cancer carcinogenesis and the role of sEV proteins in fallopian tube reproductive functions. Full article

(This article belongs to the Special Issue Bioengineering Technologies to Advance Reproductive Health)

► Show Figures

Graphical abstract

Open AccessArticle

Placenta-Targeted Nanoparticles Loaded with PFKFB3 Overexpression Plasmids Enhance Angiogenesis and Placental Function

and

Bioengineering 2022, 9(11), 652; https://doi.org/10.3390/bioengineering9110652 - 04 Nov 2022

Cited by 1 | Viewed by 771

Abstract

Placental angiogenesis disorder and placental dysplasia are important causes of many pregnancy complications. Due to safety and economic benefits, effective treatment strategies are currently limited. PFKFB3 is a key regulator of glycolysis that controls angiogenesis through a metabolic pathway independent of genetic signals. In this study, we constructed the nanodrug T-NP_PFKFB3 and explored its feasibility to promote angiogenesis and enhance placental function. First, liposomes containing PFKFB3 overexpression plasmids modified by the placental homing peptide CGKRK were synthesized by the thin film method. In vivo experiments revealed that T-NP_PFKFB3 injected intravenously specifically accumulated in the mouse placenta and therein upregulated the expression of PFKFB3 without affecting its expression in other important organs. In addition, T-NP_PFKFB3 promoted placental angiogenesis and increased the fetal and placental weights of the mice. Finally, we evaluated the safety of T-NP_PFKFB3. The expression levels of ALS/AST/BUN in the sera of pregnant mice were not significantly different from those in the sera of control group mice. However, T-NP_PFKFB3 did not cause obvious fetal abnormalities or alter the average litter size. In conclusion, T-NP_PFKFB3 can specifically target the placenta, promote angiogenesis, and enhance placental function without obvious side effects. Therefore, it has potential as a new strategy for the treatment of pregnancy complications. Full article

(This article belongs to the Special Issue Bioengineering Technologies to Advance Reproductive Health)

► Show Figures

Journal Menu

Journal Browser

Special Issue "Bioengineering Technologies to Advance Reproductive Health"

Share This Special Issue

Special Issue Editor

Special Issue Information

Keywords

Published Papers (3 papers)

Research

Further Information

Guidelines

MDPI Initiatives

Follow MDPI